Norway· NO-ID_B34D6918-EF03-48D5-804F-4B05196C8E0F
Gardasil 9
A humaner papillomvirus (typen 6, 11, 16, 18, 31, 33, 45, 52, 58) product containing human papillomavirus type 31 l1 protein + human papillomavirus type 33 l1 protein + human papillomavirus type 45 l1 protein + human papillomavirus type 52 l1 protein + human papillomavirus type 58 l1 protein + human papillomavirus type 6 l1 protein + human papillomavirus type 11 l1 protein + human papillomavirus type 16 l1 protein + human papillomavirus type 18 l1 protein + amorphous aluminium hydroxyphosphate sulphate, registered in Norway by Merck Sharp & Dohme B.V. The same ATC class is registered in 10 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Humaner papillomvirus (typen 6, 11, 16, 18, 31, 33, 45, 52, 58) is registered in 10 of 19 countries.
Countries holding a registration under ATC J07BM03 (humaner papillomvirus (typen 6, 11, 16, 18, 31, 33, 45, 52, 58)), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Humaner papillomvirus (typen 6, 11, 16, 18, 31, 33, 45, 52, 58) · ATC J07BM03
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FEST (Norway)- Active substance
- Human Papillomavirus Type 31 L1 Protein + Human Papillomavirus Type 33 L1 Protein + Human Papillomavirus Type 45 L1 Protein + Human Papillomavirus Type 52 L1 Protein + Human Papillomavirus Type 58 L1 Protein + Human Papillomavirus Type 6 L1 Protein + Human Papillomavirus Type 11 L1 Protein + Human Papillomavirus Type 16 L1 Protein + Human Papillomavirus Type 18 L1 Protein + Amorphous Aluminium Hydroxyphosphate Sulphate
- Manufacturer
- Merck Sharp & Dohme B.V
- Country
- Norway (NO)
- ATC code
- J07BM03
- ATC class
- Humaner Papillomvirus (Typen 6, 11, 16, 18, 31, 33, 45, 52, 58)
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- October 2, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_B34D6918-EF03-48D5-804F-4B05196C8E0F
- no_varenummer5086340.5NOK 1713.6
- gtin191778016178
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07BM03
Humaner papillomvirus (typen 6, 11, 16, 18, 31, 33, 45, 52, 58), as other registers publish it.
- IcelandGardasilMerck Sharp & Dohme B.V.*
- NorwayGardasil 9Orifarm AS
- FinlandGardasil 9Merck Sharp & Dohme B.V.
- FinlandGardasil 9Merck Sharp & Dohme B.V.
- PolandGardasil 9Merck Sharp & Dohme B.V.
- BelgiumGardasil 9Merck Sharp & Dohme
- FinlandGardasil 9Merck Sharp & Dohme B.V.
- IcelandGardasil 9Merck Sharp & Dohme B.V.*
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/01a0be98-dac3-4afd-9364-2a42d2b77fd5 GET /v1/drugs/01a0be98-dac3-4afd-9364-2a42d2b77fd5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, suspensjon i ferdigfylt sprøyte",
"source": "fest",
"status": "A",
"atc_name": "Papillomavirus (human typer 6, 11, 16, 18, 31, 33, 45, 52, 58)",
"merkevare_id": "ID_B34D6918-EF03-48D5-804F-4B05196C8E0F",
"name_form_strength": "Gardasil 9 inj væske, susp",
"prescription_group": "C"
}See everything about humaner papillomvirus (typen 6, 11, 16, 18, 31, 33, 45, 52, 58).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.